Multibagger Pharma Stock Hit 52-Week High As Board Announces Stock Split From Rs 5 to Rs 2 and Stellar Quarterly Results (Q2FY25) and Half-Yearly Results (H1FY25)
The stock is up by 85 per cent from its 52-week low of Rs 270.05 per share and gave multibagger returns of 1,895 per cent in 5 years.
Jagsonpal Pharmaceuticals Limited has announced plans to sub-divide or stock split its existing equity shares from a face value of Rs 5 to Rs 2 each. This move aims to increase liquidity and make the company's shares more accessible to smaller investors. The decision will be subject to the approval of the company's shareholders through a postal ballot. The record date for the subdivision or split will be determined after securing the necessary shareholder approval. The company expects to complete this process within three months from the date of shareholder approval.
Additionally, the company announced stellar Quarterly Results (Q2FY25) and half-yearly results (H1FY25). According to quarterly results, the net sales increased by 29.2 per cent to Rs 74.7 crore and net profit increased by 52 per cent to Rs 11.4 crore in Q2FY25 compared to Q2FY24. In its half-yearly results, the net sales increased by 15.3 per cent to Rs 136.1 crore and net profit increased by 12 per cent to Rs 16.8 crore in H1FY25 compared to H1FY24.
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.
Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over four decades in the Indian pharmaceutical market. The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, Dermatology and Child-care segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst the Top 5 brands in the molecule category, an extensive pan-India presence and an experienced sales team of over 900 professionals.
The company has a market cap of over Rs 1,260 crore and has been maintaining a healthy dividend payout of 54.5 per cent. The stock is up by 85 per cent from its 52-week low of Rs 270.05 per share and gave multibagger returns of 1,895 per cent in 5 years. Investors should keep an eye on this small-cap stock.
Disclaimer: The article is for informational purposes only and not investment advice.